HomeCompareVONHF vs ABBV

VONHF vs ABBV: Dividend Comparison 2026

VONHF yields 5.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $69.9K in total portfolio value
10 years
VONHF
VONHF
● Live price
5.37%
Share price
$69.62
Annual div
$3.74
5Y div CAGR
6.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$1,525.89
Full VONHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VONHF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVONHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VONHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VONHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VONHF
Annual income on $10K today (after 15% tax)
$456.56/yr
After 10yr DRIP, annual income (after tax)
$1,297.01/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,759.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VONHF + ABBV for your $10,000?

VONHF: 50%ABBV: 50%
100% ABBV50/50100% VONHF
Portfolio after 10yr
$67.4K
Annual income
$13,148.83/yr
Blended yield
19.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VONHF
Analyst Ratings
1
Hold
1
Sell
Consensus: Hold
Altman Z
0.3
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VONHF buys
0
ABBV buys
0
No recent congressional trades found for VONHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVONHFABBV
Forward yield5.37%3.06%
Annual dividend / share$3.74$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR6.1%40.6%
Portfolio after 10y$32.4K$102.3K
Annual income after 10y$1,525.89$24,771.77
Total dividends collected$9.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: VONHF vs ABBV ($10,000, DRIP)

YearVONHF PortfolioVONHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,270$569.89$11,550$430.00$280.00ABBV
2$12,696$636.86$13,472$627.96$776.00ABBV
3$14,296$711.39$15,906$926.08$1.6KABBV
4$16,091$794.31$19,071$1,382.55$3.0KABBV
5$18,104$886.53$23,302$2,095.81$5.2KABBV
6$20,360$989.04$29,150$3,237.93$8.8KABBV
7$22,888$1,102.95$37,536$5,121.41$14.6KABBV
8$25,720$1,229.48$50,079$8,338.38$24.4KABBV
9$28,890$1,369.97$69,753$14,065.80$40.9KABBV
10$32,438$1,525.89$102,337$24,771.77$69.9KABBV

VONHF vs ABBV: Complete Analysis 2026

VONHFStock

Vontobel Holding AG provides various financial services to private and institutional clients. The company operates through Asset Management, Platforms & Services, Wealth Management, and Digital Investing segments. The Wealth Management segment offers managed solutions, advisory services, and investment products; and financial planning and consulting, pension planning, succession planning, and estate planning solutions, as well as real estate financing and Lombard loans. The Asset Management segment provides equities, fixed income, multi asset, and fund solutions. The Platforms & Services segment offers various platforms, such as EAMNet, an integrated and centralized product and services platform that provides trading, and reports to research services; deritrade, a multi-issuer platform that offers designing and issuing bespoke structured products; cosmofunding, a money and capital market platform that provides securitization of classic loan and private placement; investerest, a social investing market place; derifactory, a white-labeling platform for structured products; and electronic trading solutions for professionals, as well as structured investments, funds, investment strategy/research, EAM, ESG, and ESG insights and news solutions. The Digital Investing segment provides Vontobel Volt, a digital wealth management platform; investerest, a social investing market place that combines and standardizes the entire strategy and investment spectrum; and structured and leverage investment services. Vontobel Holding AG was founded in 1924 and is headquartered in Zurich, Switzerland.

Full VONHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VONHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VONHF vs SCHDVONHF vs JEPIVONHF vs OVONHF vs KOVONHF vs MAINVONHF vs JNJVONHF vs MRKVONHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.